Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7997184 | 0.92 | KDM4E (0.68) | KDM4EALOX15TSHRSIRT1HDAC1 | |
| SCHEMBL7995733 | 0.90 | HDAC6 (0.67) | KDM4EALOX15TSHRSIRT1HDAC1 | |
| SCHEMBL315339 | 0.86 | KDM4E (1.00) | KDM4EALOX15TSHRSIRT1HDAC1 | |
| SCHEMBL31188916 | 0.86 | KDM4E (1.00) | KDM4EALOX15TSHRSIRT1HDAC1 | |
| SCHEMBL6681752 | 0.85 | KDM4E (0.55) | KDM4EALOX15TSHRSIRT1DRD2 | |
| SCHEMBL15233568 | 0.84 | KDM4E (0.75) | KDM4EALOX15TSHRSIRT1HDAC1 | |
| SCHEMBL5034166 | 0.84 | KDM4E (0.60) | KDM4EALOX15TSHRSIRT1HDAC1 | |
| SCHEMBL29676812 | 0.84 | KDM4E (0.60) | KDM4EALOX15TSHRSIRT1HDAC1 | |
| SCHEMBL30073106 | 0.83 | KDM4E (0.72) | KDM4EALOX15TSHRSIRT1SMN1; SMN2 | |
| SCHEMBL30073110 | 0.83 | KDM4E (0.72) | KDM4EALOX15TSHRSIRT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | claimed |
| CN-1731997-A | Methods of treating and controlling macular degeneration using compositions comprising selective cytokine inhibitory drugs | CELGENE CORP (US) | 2006-02-08 | — | — | CN | claimed |
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| CN-102387798-A | Methods of use of PDE4 modulators for the treatment, prevention and management of tuberculosis and compositions comprising the same | CELGENE CORP | 2012-03-21 | — | — | CN | disclosed |
| CN-1780616-B | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | CELGENE CORP | 2010-05-12 | — | — | CN | disclosed |
| CN-101309585-A | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury | CELGENE CORP (US) | 2008-11-19 | — | — | CN | disclosed |
| CN-101111235-A | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management airway inflammation | CELGENE CORP (US) | 2008-01-23 | — | — | CN | disclosed |
| CN-1984652-A | Using methods and compositions comprising selective cytokine inhibitory drugs for treatment and management of myeloproliferative diseases | CELGENE CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1984651-A | Methods and compositions for treatment and management of cancer and other diseases using selective cytokine inhibitory drugs | CELGENE CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1972684-A | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | CELGENE CORP (US) | 2007-05-30 | — | — | CN | disclosed |
| CN-1972686-A | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes | CELGENE CORP (US) | 2007-05-30 | — | — | CN | disclosed |
| CN-1738614-A | Compositions comprising (-) -3- (3, 4-dimethoxy-phenyl) -3- (1-oxo-1, 3-dihydro-isoindol-2-yl) -propionamide and methods of use thereof | CELGENE CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| CN-1731997-A | Methods of treating and controlling macular degeneration using compositions comprising selective cytokine inhibitory drugs | CELGENE CORP (US) | 2006-02-08 | — | — | CN | disclosed |
| CN-1731998-A | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORP (US) | 2006-02-08 | — | — | CN | disclosed |
| CN-1713905-A | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome | CELGENE CORP (US) | 2005-12-28 | — | — | CN | disclosed |
| CN-1705439-A | Modulation of stem and progenitor cell differentiation, assays, and uses thereof | CELGENE CORP (US) | 2005-12-07 | — | — | CN | disclosed |
| CN-1668296-A | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | CELGENE CORP (US) | 2005-09-14 | — | — | CN | disclosed |
| EP-1567154-A2 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| CN-1658848-A | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds | CELGENE CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| WO-2004043378-A2 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | GPR119, GLS, GCKR | KDM4E 2872/4885ALOX15 3059/4885TSHR 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.